Journal article

Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer

Angelyn Anton, Olfat Kamel Hasan, Zita Ballok, Patrick Bowden, Anthony J Costello, Laurence Harewood, Niall M Corcoran, Phil Dundee, Justin S Peters, Nathan Lawrentschuk, Andrew Troy, David Webb, Yee Chan, Andrew See, Shankar Siva, Declan Murphy, Michael S Hofman, Ben Tran

BJU INTERNATIONAL | WILEY | Published : 2020


Prostate-specific membrane antigen (PSMA) PET/CT imaging is increasingly being utilised in clinical practice, demonstrating greater sensitivity in the detection of metastatic prostate cancer (mPC) compared to conventional imaging [1]. Prior studies have primarily focussed on its use following biochemical recurrence to detect oligometastatic disease potentially amenable to salvage therapies [2-4]. However, the role of PSMA PET/CT in assessing treatment response remains unclear. Standardised criteria for metabolic response have not been established, particularly to account for whole body tumour burden and the effects of systemic therapies on PSMA expression.